Effect of recombinant human thyroid stimulating hormone on radioactive iodine uptake by thyroid carcinoma in dogs

IF 2.1 2区农林科学 Q1 VETERINARY SCIENCES

Journal of Veterinary Internal Medicine Pub Date : 2024-06-21 DOI:10.1111/jvim.17132

Stephanie Scheemaeker, Kathelijne Peremans, Eva Vandermeulen, Luc Duchateau, Tom Roggeman, Sylvie Daminet

{"title":"Effect of recombinant human thyroid stimulating hormone on radioactive iodine uptake by thyroid carcinoma in dogs","authors":"Stephanie Scheemaeker, Kathelijne Peremans, Eva Vandermeulen, Luc Duchateau, Tom Roggeman, Sylvie Daminet","doi":"10.1111/jvim.17132","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The high doses of radioiodine-131 (<sup>131</sup>I) and, subsequently, the high radioactive burden for dog and environment warrants optimization of <sup>131</sup>I therapy in dogs with thyroid carcinoma (TC).</p>\n </section>\n \n <section>\n \n <h3> Hypothesis/Objectives</h3>\n \n <p>To evaluate the effect of a revised protocol with recombinant human thyroid stimulating hormone (rhTSH) on tumor radioactive iodine uptake (RAIU) in dogs with TC.</p>\n </section>\n \n <section>\n \n <h3> Animals</h3>\n \n <p>Nine client-owned dogs diagnosed with TC.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A prospective cross-over study in which tumor RAIU was calculated and compared at 8 hours (8h-RAIU) and 24 hours (24h-RAIU) after injection of radioactive iodine-123 (<sup>123</sup>I), once with and once without rhTSH (ie, 250 μg, IM, 24 and 12 hours before <sup>123</sup>I) in each dog. Simultaneously, serum total thyroxine (TT4) and TSH were measured at baseline (T<sub>0</sub>), and 6 (T<sub>6</sub>), 12 (T<sub>12</sub>), 24 (T<sub>24</sub>), and 48 hours (T<sub>48</sub>) after the first rhTSH administration.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Tumor RAIU was significantly higher at 24 hours with rhTSH compared to no rhTSH (mean difference = 8.85%, 95% CI of [1.56; 16.14]; <i>P</i> = .03), while this was non-significant at 8 hours (mean difference = 4.54%, 95% CI of [0.35; 8.73]; <i>P</i> = .05). A significant change of serum TT4 (median difference T<sub>24</sub> − T<sub>0</sub> = 35.86 nmol/L, interquartile range [IQR] = 15.74 nmol/L) and TSH (median difference T<sub>24</sub> − T<sub>0</sub> = 1.20 ng/mL, IQR = 1.55 ng/mL) concentrations occurred after administration of rhTSH (<i>P</i> < .001).</p>\n </section>\n \n <section>\n \n <h3> Conclusions and Clinical Importance</h3>\n \n <p>Recombinant human TSH could optimize <sup>131</sup>I treatment in dogs with TC by increasing tumor RAIU and thus <sup>131</sup>I treatment efficacy.</p>\n </section>\n </div>","PeriodicalId":49958,"journal":{"name":"Journal of Veterinary Internal Medicine","volume":"38 4","pages":"2273-2281"},"PeriodicalIF":2.1000,"publicationDate":"2024-06-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvim.17132","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Veterinary Internal Medicine","FirstCategoryId":"97","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jvim.17132","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The high doses of radioiodine-131 (¹³¹I) and, subsequently, the high radioactive burden for dog and environment warrants optimization of ¹³¹I therapy in dogs with thyroid carcinoma (TC).

Hypothesis/Objectives

To evaluate the effect of a revised protocol with recombinant human thyroid stimulating hormone (rhTSH) on tumor radioactive iodine uptake (RAIU) in dogs with TC.

Animals

Nine client-owned dogs diagnosed with TC.

Methods

A prospective cross-over study in which tumor RAIU was calculated and compared at 8 hours (8h-RAIU) and 24 hours (24h-RAIU) after injection of radioactive iodine-123 (¹²³I), once with and once without rhTSH (ie, 250 μg, IM, 24 and 12 hours before ¹²³I) in each dog. Simultaneously, serum total thyroxine (TT4) and TSH were measured at baseline (T₀), and 6 (T₆), 12 (T₁₂), 24 (T₂₄), and 48 hours (T₄₈) after the first rhTSH administration.

Results

Tumor RAIU was significantly higher at 24 hours with rhTSH compared to no rhTSH (mean difference = 8.85%, 95% CI of [1.56; 16.14]; P = .03), while this was non-significant at 8 hours (mean difference = 4.54%, 95% CI of [0.35; 8.73]; P = .05). A significant change of serum TT4 (median difference T₂₄ − T₀ = 35.86 nmol/L, interquartile range [IQR] = 15.74 nmol/L) and TSH (median difference T₂₄ − T₀ = 1.20 ng/mL, IQR = 1.55 ng/mL) concentrations occurred after administration of rhTSH (P < .001).

Conclusions and Clinical Importance

Recombinant human TSH could optimize ¹³¹I treatment in dogs with TC by increasing tumor RAIU and thus ¹³¹I treatment efficacy.

Abstract Image

查看原文本刊更多论文

重组人促甲状腺激素对狗甲状腺癌放射性碘吸收的影响

背景高剂量的放射性碘-131（131I）以及随之而来的对狗和环境的高放射性负荷要求对甲状腺癌（TC）狗的131I治疗进行优化。假设/目的评估使用重组人促甲状腺激素（rhTSH）的修订方案对TC狗肿瘤放射性碘摄取（RAIU）的影响。方法进行前瞻性交叉研究，计算并比较每只狗在注射放射性碘-123（123I）后 8 小时（8h-RAIU）和 24 小时（24h-RAIU）的肿瘤放射性碘摄取量（RAIU）。同时，在基线（T0）、首次注射 rhTSH 后 6 小时（T6）、12 小时（T12）、24 小时（T24）和 48 小时（T48）测量血清总甲状腺素（TT4）和促甲状腺激素（TSH）。结果与不使用 rhTSH 相比，使用 rhTSH 24 小时后肿瘤 RAIU 明显升高（平均差异 = 8.85%，95% CI 为 [1.56; 16.14]；P = .03），而 8 小时后差异不明显（平均差异 = 4.54%，95% CI 为 [0.35; 8.73]；P = .05）。服用 rhTSH 后，血清 TT4（中位数差异 T24 - T0 = 35.86 nmol/L，四分位数间距 [IQR] = 15.74 nmol/L）和 TSH（中位数差异 T24 - T0 = 1.20 ng/mL，IQR = 1.55 ng/mL）浓度发生了明显变化（P < .001）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Veterinary Internal Medicine 农林科学-兽医学

CiteScore

4.50

自引率

11.50%

发文量

243

审稿时长

22 weeks

期刊介绍： The mission of the Journal of Veterinary Internal Medicine is to advance veterinary medical knowledge and improve the lives of animals by publication of authoritative scientific articles of animal diseases.